|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: the avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010.PubMed/NCBI
|
|
3
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: a clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shah U and Morrison T: A review of the
symptomatic management of malignant gliomas in adults. J Natl Compr
Cancer Netw. 11:424–429. 2013.PubMed/NCBI
|
|
5
|
Eyüpoglu IY, Buchfelder M and Savaskan NE:
Surgical resection of malignant gliomas-role in optimizing patient
outcome. Nat Rev Neurol. 9:141–151. 2013.PubMed/NCBI
|
|
6
|
Grimm SA and Chamberlain MC: Brainstem
glioma: a review. Curr Neurol Neurosci Rep. 13:3462013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
He J, Liu Y and Lubman DM: Targeting
glioblastoma stem cells: cell surface markers. Curr Med Chem.
19:6050–6055. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding XW, Wu JH and Jiang CP: ABCG2: a
potential marker of stem cells and novel target in stem cell and
cancer therapy. Life Sci. 86:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh SK, Hawkins C, Clarke ID, et al:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan X, Curtin J, Xiong Y, et al:
Isolation of cancer stem cells from adult glioblastoma multiforme.
Oncogene. 23:9392–9400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bidlingmaier S, Zhu X and Liu B: The
utility and limitations of glycosylated human CD133 epitopes in
defining cancer stem cells. J Mol Med (Berl). 86:1025–1032. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beier D, Schulz JB and Beier CP:
Chemoresistance of glioblastoma cancer stem cells - much more
complex than expected. Mol Cancer. 10:1282011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen SL, You J and Wang GJ: Supercritical
fluid extraction of β-elemene under lower pressure. Se Pu.
19:179–181. 2001.(In Chinese).
|
|
15
|
Zhang X, Zhang Y and Li Y: β-elemene
decreases cell invasion by upregulating E-cadherin expression in
MCF-7 human breast cancer cells. Oncol Rep. 30:745–750. 2013.
|
|
16
|
Bao F, Qiu J and Zhang H: Potential role
of β-elemene on histone H1 in the H22 ascites hepatoma cell line.
Mol Med Rep. 6:185–190. 2012.
|
|
17
|
Zhu T, Zhao Y, Zhang J, Li L, Zou L, Yao Y
and Xu Y: β-Elemene inhibits proliferation of human glioblastoma
cells and causes cell-cycle G0/G1 arrest via mutually compensatory
activation of MKK3 and MKK6. Int J Oncol. 38:419–426. 2011.
|
|
18
|
Yao YQ, Ding X, Jia YC, Huang CX, Wang YZ
and Xu YH: Anti-tumor effect of beta-elemene in glioblastoma cells
depends on p38 MAPK activation. Cancer Lett. 264:127–134. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu T, Xu Y, Dong B, Zhang J, Wei Z, Xu Y
and Yao Y: β-elemene inhibits proliferation of human glioblastoma
cells through the activation of gliamaturation factor β and induces
sensitization to cisplatin. Oncol Rep. 26:405–413. 2011.
|
|
20
|
Yao YQ, Xu YH, Lu J, Zhou HY and Wang YZ:
Effect of p38 MAPK on elemene-induced cell cycle arrest in C6
glioblastoma cells. Zhonghua Yi Xue Za Zhi. 88:56–58. 2008.(In
Chinese).
|
|
21
|
Zhao YS, Zhu TZ, Yao YQ, et al: β-elemene
inhibits Hsp90/Raf-1 molecular complex inducing apoptosis of
glioblastoma cells. J Neurooncol. 107:307–314. 2012.
|
|
22
|
Zhang L and Zhang RH: Investigation of
Tca8113 cell lines differentiation induced by β-elemene. J Oral Sci
Res. 18:307–309. 2002.(In Chinese).
|
|
23
|
Fang Z, Chen HS, Chen HB and Liu YM:
β-Elemene induced differentiation of PLA801D cell lines. Chin J
Gerontol. 28:768–769. 2008.(In Chinese).
|
|
24
|
Wang HM, Yang XJ, Dong XT, et al:
Correlation between the distribution of CD133-positive cells and
the proliferation of microvessels in glioblastoma multiforme.
Zhonghua Yi Xue Za Zhi. 91:781–785. 2011.(In Chinese).
|
|
25
|
He H, Niu CS and Li MW: Correlation
between glioblastoma stem-like cells and tumor vascularization.
Oncol Rep. 27:45–50. 2012.PubMed/NCBI
|
|
26
|
Carrasco-Garcia E, Sampron N, Aldaz P, et
al: Therapeutic strategies targeting glioblastoma stem cells.
Recent Pat Anticancer Drug Discov. 8:216–227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gal H, Makovitzki A, Amariglio N, Rechavi
G, Ram Z and Givol D: A rapid assay for drug sensitivity of
glioblastoma stem cells. Biochem Biophys Res Commun. 358:908–913.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sampetrean O and Saya H: Characteristics
of glioma stem cells. Brain Tumor Pathol. 30:209–214. 2013.
View Article : Google Scholar
|
|
29
|
Salmaggi A, Boiardi A, Gelati M, et al:
Glioblastoma-derived tumorospheres identify a population of tumor
stem-like cells with angiogenic potential and enhanced multidrug
resistance phenotype. Glia. 54:850–860. 2006. View Article : Google Scholar
|
|
30
|
Choy W, Nagasawa DT, Trang A, Thill K,
Spasic M and Yang I: CD133 as a marker for regulation and potential
for targeted therapies in glioblastoma multiforme. Neurosurg Clin N
Am. 23:391–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang B, Sun J, Yu SP, et al:
Rac1+ cells distributed in accordance with
CD133+ cells in glioblastomas and the elevated
invasiveness of CD133+ glioma cells with higher Rac1
activity. Chin Med J (Engl). 125:4344–4348. 2012.
|
|
32
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
33
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
34
|
Bleau AM, Huse JT and Holland EC: The
ABCG2 resistance network of glioblastoma. Cell Cycle. 8:2936–2944.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scharenberg CW, Harkey MA and Torok-Storb
B: The ABCG2 transporter is an efficient Hoechst 33342 efflux pump
and is preferentially expressed by immature human hematopoietic
progenitors. Blood. 99:507–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nakanishi T and Ross DD: Breast cancer
resistance protein (BCRP/ABCG2): its role in multidrug resistance
and regulation of its gene expression. Chin J Cancer. 31:73–99.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang L, Wu X, Xu T, Luo C, Qian J and Lu
Y: Chemotherapy plus radiotherapy versus radiotherapy alone in
patients with anaplastic glioma: a systematic review and
meta-analysis. J Cancer Res Clin Oncol. 139:719–726. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hau P, Koch D, Hundsberger T, et al:
Safety and feasibility of long-term temozolomide treatment in
patients with high-grade glioma. Neurology. 68:688–690. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hart MG, Garside R, Rogers G, Stein K and
Grant R: Temozolomide for high grade glioma. Cochrane Database Syst
Rev. 4:CD0074152013.
|
|
41
|
Eramo A, Ricci-Vitiani L, Zeuner A, et al:
Chemotherapy resistance of glioblastoma stem cells. Cell Death
Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Clement V, Sanchez P, de Tribolet N,
Radovanovic I and Ruiz i Altaba A: HEDGEHOG-GLI1 signaling
regulates human glioma growth, cancer stem cell self-renewal, and
tumorigenicity. Curr Biol. 17:165–172. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brada M, Judson I, Beale P, et al: Phase I
dose-escalation and pharmacokinetic study of temozolomide (SCH
52365) for refractory or relapsing malignancies. Br J Cancer.
81:1022–1030. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang H, Song N, Liu YP, Qu XJ, Hou KZ,
Teng YE and Zhang JD: Reversal of resistance to adriamycin in human
gastric cancer by β-elemene. J Chian Med Univ. 40:968–993. 2011.(In
Chinese).
|
|
46
|
Li X, Wang G, Zhao J, et al:
Antiproliferative effect of beta-elemene in chemoresistant ovarian
carcinoma cells is mediated through arrest of the cell cycle at the
G2-M phase. Cell Mol Life Sci. 62:894–904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tao L, Zhou L, Zheng LY and Yao M:
Inhibition of eIF families expression and angiogenesis for human
laryngeal carcinoma by elemene administration. Zhonghua Er Bi Yan
Hou Tou Jing Wai Ke Za Zhi. 40:840–845. 2005.(In Chinese).
|
